INO · Inovio Pharmaceuticals, Inc.
$1.10
+0.01 (+0.92%)
At close · Jul 21
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the late fourth quarter of 2026.”View the 10-Q filed May 13, 2026
Market Cap
$90.50M
Shares
82.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jacqueline Shea | CEO | $1,587,155 |
| Michael Sumner | Chief Medical Officer | $910,636 |
| Peter D. Kies | CFO | $833,684 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jacqueline Shea | CEO | $2,050,669 |
| Michael Sumner | Chief Medical Officer | $1,037,406 |
| Peter D. Kies | CFO | $940,072 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jacqueline Shea | CEO | $2,438,908 |
| Peter D. Kies | CFO | $1,161,040 |
| Laurent M. Humeau | Chief Scientific Officer | $1,144,927 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | CEO | $10,472,297 |
| Jacqueline Shea | CEO | $3,519,118 |
| Peter D. Kies | CFO | $1,618,468 |
| Laurent M. Humeau | Chief Scientific Officer | $1,570,461 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | CEO | $6,223,600 |
| Jacqueline Shea | CEO | $2,310,157 |
| Peter D. Kies | CFO | $2,297,817 |
| Laurent M. Humeau | Chief Scientific Officer | $2,283,569 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | CEO | $4,707,676 |
| Peter D. Kies | CFO | $2,153,905 |
| Laurent M. Humeau | Chief Scientific Officer | $2,137,365 |
| Jacqueline Shea | COO | $2,137,311 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | CEO | $2,588,534 |
| Mark L. Bagarazzi | Former Chief Medical Officer | $2,324,930 |
| Jacqueline Shea | COO | $1,157,034 |
| Peter D. Kies | CFO | $1,142,936 |
| Laurent M. Humeau | Chief Scientific Officer | $972,531 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | CEO | $3,081,043 |
| Mark L. Bagarazzi | Former Chief Medical Officer | $1,345,888 |
| Peter D. Kies | CFO | $1,331,612 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| J. Joseph Kim | CEO | $4,389,268 |
| Peter D. Kies | CFO | $1,447,387 |
| Mark L. Bagarazzi | Former Chief Medical Officer | $1,444,719 |
Key facts
CIK
1055726
CUSIP
45773H409
13F (30d)
10 filings
10 filers
Visit website
Investor relations